부산대학교 도서관

Background:?Prognostic significance between progression LVH and clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) is uncertain. This study aimed to investigate prognostic impact of progression of LV mass index (LVMI) in patients with STEMI.?Methods:?We analyzed the data and clinical outcomes of patients with STEMI who received successful coronary intervention. We finally enrolled 200 patients (166 males, 56 ±11 year-old) performed echocardiographic follow-up (F/U) between 12 and 36 months. According to the change in LVMI compared with baseline LVMI, patients were classified into progressed LVMI group and no progressed LVMI group. Progression of LVMI was defined as increment of LMVI greater than 10% compared with the baseline LVMI. Occurrence of major adverse cardiovascular events (MACE; death, recurrent MI, target vessel revascularization (TVR) within 5 years was evaluated. Results:?Progression of LVMI was occurred in 55 patients (42 males, 55±11 year-old). The event-free survival of all-cause mortality and recurrent MI in the progressed LVMI group was significantly worse than the no progressed LVMI group (log-rank p＝0.002 and 0.005 figure). In a cox-regression model, the progressed LVMI group was associated with increased risk for recurrent MI (HR, 5.794; 95% CI, 1.445-23.239, p＝0.013). By multivariate logistic regression, initial LVMI (odds ratio [OR], 1.012; 95% confidence interval [CI], 1.000-1.023; p＝0.047] and F/U LVMI (OR, 1.016; 95%CI, 1.000-1.032, p＝0.049) were independent predictors for MACE. Progression of LVMI was only independent predictor of MI (OR, 6.069; 95% CI, 1.426-25.822, p＝0.015).?Conclusions:?In present study, increased LVMI was an independent predictor for adverse events, especially for recurrent MI, in patients with STEMI who received successful coronary intervention.